Renaissance Technologies
KLRS

Renaissance Technologies’s Kalaris Therapeutics KLRS Stock Holding History

Renaissance Technologies’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$382K Sell
66,151
-21,600
-25% -$192K ﹤0.01% 2716
2025
Q4 		$741K Sell
87,751
-25,000
-22% -$160K ﹤0.01% 2413
2025
Q3 		$652K Buy
112,751
+16,000
+17% +$52.9K ﹤0.01% 2684
2025
Q2 		$258K Buy
96,751
+77,500
+403% +$350K ﹤0.01% 3087
2025
Q1 		$155K Buy
19,251
+2,748
+17% +$26.9K ﹤0.01% 3124
2024
Q4 		$159K Sell
16,503
-17,273
-51% -$261K ﹤0.01% 3219
2024
Q3 		$628K Sell
33,776
-624
-2% -$10.9K ﹤0.01% 2682
2024
Q2 		$572K Sell
34,400
-3,056
-8% -$54K ﹤0.01% 2631
2024
Q1 		$650K Buy
37,456
+4,327
+13% +$70.6K ﹤0.01% 2752
2023
Q4 		$518K Buy
33,129
+18,619
+128% +$734K ﹤0.01% 2751
2023
Q3 		$718K Buy
14,510
+1,158
+9% +$78.9K ﹤0.01% 2520
2023
Q2 		$1.04M Sell
13,352
-6,118
-31% -$582K ﹤0.01% 2444
2023
Q1 		$1.76M Buy
19,470
+1,479
+8% +$188K ﹤0.01% 2101
2022
Q4 		$2.12M Buy
17,991
+5,356
+42% +$908K ﹤0.01% 2029
2022
Q3 		$2.29M Sell
12,635
-482
-4% -$75.1K ﹤0.01% 1928
2022
Q2 		$1.18M Buy
13,117
+10,808
+468% +$1.13M ﹤0.01% 2602
2022
Q1 		$358K Buy
+2,309
New +$461K ﹤0.01% 3387
2021
Q3 		– Sell
-1,217
Closed -$553K – 3922
2021
Q2 		$553K Buy
+1,217
New +$628K ﹤0.01% 2924

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Renaissance Technologies's KLRS Position: Q1 2026 in Review

Renaissance Technologies reduced its Kalaris Therapeutics (KLRS) stake by 25% in Q1 2026, selling an estimated $192K and leaving 66,151 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #2716.

Renaissance Technologies first reported a position in KLRS in Q2 2021 and has held it in 18 quarters since. The position peaked at $2.29M in Q3 2022. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Renaissance Technologies held 66,151 shares of Kalaris Therapeutics worth $382K as of Q1 2026.
  • Renaissance Technologies sold 21,600 Kalaris Therapeutics shares in Q1 2026, an estimated $192K.
  • Kalaris Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2716 holding.
  • Renaissance Technologies first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • Renaissance Technologies's Kalaris Therapeutics position peaked at $2.29M in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.